Clinical significance of detecting elevated serum DcR3/TR6/M68 in malignant tumor patients
Authors:
Open Access
- 1 April 2003
- journal article
- research article
- Published by Wiley in International Journal of Cancer
- Vol. 105 (5) , 724-732
Abstract
TR6/DcR3/M68 is a soluble receptor that belongs to the TNF receptor family. It is expressed in malignant cells of several tumor types and has been postulated to help tumor cells to gain survival advantage by inhibiting apoptosis and by interfering with immune surveillance. In our study, we assessed for the first time serum TR6 in tumor patients to explore its diagnostic and prognostic value. We examined serum TR6 levels with ELISA in 146 tumor patients, 19 patients with acute infection, 5 patients with liver cirrhosis and 29 healthy individuals. TR6 expression in tumor mass was studied with immunohistochemistry. TR6 gene copy number in tumor tissues was evaluated by real time PCR. Ninety‐seven point nine percent (47 of 48 cases) of healthy individuals and patients with acute infection were serum TR6‐negative. In contrast, 56.2% (82 of 146 cases) of the tumor patients were serum TR6‐positive. Almost all serum TR6‐positive individuals (98.8%, 82 out of 83 cases) had malignancy, excluding the cases of liver cirrhosis. In gastric carcinomas, serum TR6 levels were closely correlated with tumor differentiation status and TNM classification. Tumor mass was the source of serum TR6 because its levels decreased drastically after curative tumor resection. TR6 gene amplification occurred in about half of liver carcinomas, but not in gastric or pancreatic carcinomas, indicating plural mechanisms of TR6 upregulation. Our study demonstrated that serum TR6 should be considered as a novel parameter for the diagnosis, treatment and prognosis of malignancies.Keywords
This publication has 27 references indexed in Scilit:
- Mouse T cells receive costimulatory signals from LIGHT, a TNF family memberBlood, 2002
- Targeting the optimal extent of lymph node dissection for gastric cancerJournal of Surgical Oncology, 2002
- DCR3 locus is a predictive marker for 5-fluorouracil-based adjuvant chemotherapy in colorectal cancerInternational Journal of Cancer, 2002
- The prognostic significance of overexpression of the decoy receptor for Fas ligand (DcR3) in patients with gastric carcinomasGastric Cancer, 2002
- Targeting death and decoy receptors of the tumour-necrosis factor superfamilyNature Reviews Cancer, 2002
- TL1A Is a TNF-like Ligand for DR3 and TR6/DcR3 and Functions as a T Cell CostimulatorImmunity, 2002
- Localization of a New Prostate-specific Antigen-related Serine Protease Gene, KLK4 , Is Evidence for an Expanded Human Kallikrein Gene Family Cluster on Chromosome 19q13.3–13.4Journal of Biological Chemistry, 1999
- Epidemiology of Primary Liver CancerSeminars in Liver Disease, 1999
- LIGHT, a novel ligand for lymphotoxin beta receptor and TR2/HVEM induces apoptosis and suppresses in vivo tumor formation via gene transfer.Journal of Clinical Investigation, 1998
- Alpha-fetoprotein in the diagnosis of hepatoma.BMJ, 1978